JK07 clinical trials
Also written JK07.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses JK07 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- JK07
- 4
Studies by the year they started
4 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses JK07 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study of JK07 in Patients With Chronic Heart FailureActive, not recruitingPhase 2Salubris Biotherapeutics IncNCT06369298Written as JK07
- Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary HypertensionWithdrawnPhase 2Salubris Biotherapeutics IncNCT07221513Written as JK07
- Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)CompletedPhase 1Salubris Biotherapeutics IncNCT04210375Written as JK07
- Single-Ascending Dose Study of JK07 in Subjects With HFpEFWithdrawnPhase 1Salubris Biotherapeutics IncNCT05322616Written as JK07